Eden Romm

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

We are pleased to share details from a paper co-authored by Crescendo scientists and the Resolian team, published earlier this week in Bioanalysis Zone. In the development of novel therapeutics, establishing robust and reliable assays to understand the pharmacokinetic (PK) properties of a drug in patients is crucial. Bispecific antibody fragments present unique challenges due to the multiple targets and often reduced molecular size, which increases the complexity of assay development.   Our scientists have developed a method to quantify CB307, our first-in-class Humabody® VH bispecific targeting PSMA and CD137 in blood. This method is already being used to support our Phase 1b POTENTIA clinical trial. In this paper, we share our findings and the method development process as a case study to help the broader scientific community overcome similar challenges in developing antibody fragment-based therapeutics.   To read the full paper, visit: https://lnkd.in/e9Z-vpZN   #Cancer #Biotech #Therapeutics

30

Looking for new ways to visualize, size, and count proteins, extracellular vesicles (EVs), liposomes, lipid nanoparticles, and viruses? The California NanoSystems Institute at UCLA just enhanced its capabilities with the addition of nanoparticle tracking analysis (NTA) at the Nano and Pico Characterization Laboratory (NPC). The Horiba ViewSizer 3000 tracks nanoparticles in liquid by monitoring their heat-induced Brownian motion. Its three lasers accommodate a wide range of particle sizes (10 nanometers to 15 microns), to provide high-resolution size distribution data, concentration measurements, and tracking of specific particle subsets using fluorescent markers. We invite all researchers to leverage this state-of-the-art instrument! #NanoparticleTracking #BiomedicalResearch #UCLA #Nanotechnology #LiquidBiopsy #ExtracellularVesicles

3

Discover novel and promising methods for rational drug design with Anna Kapeliukha, our Head of the Machine Learning Department! Subscribe to her blog and stay tuned for the latest news in the world of AI.

20

"Drug development teams have found significant data and modeling challenges in regard to tackling the complexities associated with #PDIinhibitors given the challenges with creating meaningful models, and accumulating and deciphering the data," said Panna Sharma, CEO and President of Lantern Pharma. "Our #AI platform, RADR®, can increase the confidence, insights, and comfort levels in developing data-driven development paths by modeling highly complex scenarios at a scale that only has become possible recently. It’s an ideal approach for Oregon Therapeutics, which has executed a series of highly targeted in vivo and in vitro experiments and is poised to make incredibly important and patient-centric decisions about the clinical future of the molecule. That's where RADR® can play a highly essential and market defining role." https://lnkd.in/gabi_27S #biotech #businessdevelopment #artificialintelligence

1

As a selected Showcase Company from the NCI SBIR Development Center's Investor Initiative, Tezcat Biosciences will be at #BIO2024 in San Diego June 3-6. Tezcat Biosciences is developing a receptor-independent drug delivery technology, initially positioned for RAS pathway activated cancers. We are seeking industry collaborations to expand our pipeline as our technology is payload and disease agnostic. If your company has an interesting, hard to deliver payload and/or works in the following disease areas, we would like to set up a time to meet at the event. #SmallMolecule #siRNA #Radiopharmaceutical #PROTAC #Immunomodulatory #EndosomeEscape #CardiovascularDisease #MASH #NASH #InflammatoryDisease #NeurodegenerativeDisease #InfectiousDisease #AnimalHealth To schedule a time to meet inside the event, please use BIO’s One-on-One Partnering™ System. Outside the event, please DM either Dr. Craig Ramirez, Ph.D. or Dr. Andrew D. Hauser to schedule a time to meet. #biotech #businessdevelopment #networking #partnering https://lnkd.in/eEDtKaAK

14

Frontier Science - RNA Binding Proteins (RBPs) w/ Gene Yeo - Professor @ UC San Diego Delve into the forefront of RNA Biology and Therapeutics with BIOS Frontier Science! Join us as we engage in a profound discussion with esteemed Professor Gene Yeo from UC San Diego. In this episode, we'll explore the intricate landscape of RNA Binding Proteins (RBPs), shedding light on their crucial role in gene expression regulation and their promising potential as therapeutic targets. From cutting-edge technologies like eCLIP and STAMP to innovative RNA editing therapies, we'll unveil the latest advancements shaping the landscape of modern medicine. Tune in to embark on this enlightening journey Tune in: https://buff.ly/3JM7fIm #Biotech #RNA #Therapeutics #SciencePodcast

2

Merck KGaA, Darmstadt, Germany signed a deal with Israel biotech Biolojic Design, Ltd. for developing AI-driven ADCs for blocking tumor escape mechanisms, overcome tumor and patient heterogeneity and improve on safety and efficacy. Biolojic Design, Ltd. uses AI and computational design to turn human antibodies into programmable switches with specific functions such as agonism, antagonism and conditional binding. #adc #antibody #oncology #mab #antibodydrugconjugation #ai https://lnkd.in/gtYSATUH

40

Natural killer (NK) cells are promising candidates for cancer therapy due to their ability to recognize and eliminate tumor cells. However, cryopreservation diminishes NK cell function, posing challenges for their therapeutic use. This study in Nature Communications by Dr. Carl H. June and Neil C. Sheppard highlights the impact of cryopreservation on natural killer (NK) cell function in cancer therapy. Pretreating NK cells with Interleukins-15 (IL-15) and IL-18 before cryopreservation significantly improves their recovery and function by reducing granzyme B levels and inducing antiapoptotic genes. This approach offers a straightforward solution to enhance the efficacy of cryopreserved NK cell therapy. https://lnkd.in/eZavs_gs

78

1 Comment

Don’t miss this opportunity at the Gene Therapy Initiative 1st Annual Symposium on September 19, 2024 to engage our thriving San Diego community of researchers, life sciences, biotechnology and pharmaceutical companies in the gene therapy space. The Gene Therapy Initiative (GTI) Symposium will convene researchers and industry experts to share the latest scientific findings and facilitate new partnerships with the goal of expediting the delivery of stem cell and gene therapy treatments, especially for patients with rare genetic diseases. Program Highlights: *Exploratory talks on innovative gene modifying therapeutics and optimization of existing tools. *Updates on gene therapies that are the subject of academic research and commercial development. *Induced Pluripotent Stem-cell-based disease models to test gene therapies. *Interactive panel on resources and collaboration for developing therapies for rare diseases. *Opportunity to learn about 2024 GTI seed grant funded projects. *Poster session featuring faculty and student research. *Networking hour to foster connectivity amongst attendees. Please note, there is NO CME for this symposium.   For more information and to register, go to: https://lnkd.in/gJuEP_Kv #GeneTherapy #genetherapies #RNAtechnologies #ExVivoGeneTherapy #AAVgenetherapy #research #science #lifesciences #biotechnology #scientificmeeting

12

Nikki Carter, our Director of Commercial Organoid Innovation, leverages decades of experience in large pharmaceutical companies to help researchers optimize organoid-based drug discovery and high-throughput screening programs. Check out her latest published perspectives on these topics and more: https://ow.ly/Xxm350SzKrR. ✏️ A Three-Pillar Approach to Driving Organoid Adoption in Drug Discovery: https://ow.ly/y6sq50SzKrQ ✏️ Patient-Derived Organoids in Disease Modeling: https://ow.ly/RAgJ50SzKrS #3dbiology #3dcellculture #organoids #drugdiscovery #drugscreening #drugdevelopment #diseasemodeling #labautomation #ai #machinelearning #deeplearning #highcontentimaging #highcontentscreening #scienceandtechnology #pharma #geneeditting #cellculture #pdo #imageanalysis

25

2 Comments

Have things really changed in the last 200 years? Earlier we were a bottomless pit for men to fight British wars and run their colonies, and now we are reduced to graduating talent for top innovative Western R&D giants. Will we ever build anything in India with cutting edge R&D? Will our research move the needle in any field in India? The world is racing ahead, but have we evolved psychologically from centuries of colonization & humiliation to control our own destiny. I know some of the amazing folks at Xaira. Prof. Baker is the real deal and his research (I have tracked it for the last 14 years) and ambitions, alongwith available technology (he was always ahead of existing tech), can revolutionize the entire drug design industry.

9

Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancer This paper by Brian Koh and several co-authors at PrognomiQ Inc represents the largest deep multi-omics interrogation to date for lung cancer. Proteomics sample processing leveraged the Seer Proteograph Assay using a 5-nanoparticle panel followed by LC-MS analysis using a fleet of four Evosep One LC platforms from Evosep Biosystems coupled to Bruker timsTOF HT Mass Spectrometers. Samples from a cohort of 2,513 subjects was leveraged in an untargeted approach to collect and analyze over 750,000 orthogonal protein, transcript, and metabolite features to train a machine learning-based lung cancer classifier. You can read the full manuscript here: https://lnkd.in/eEcSFV3M To learn more about the Evosep One platform, visit our website www.evosep.com or reach out to me for more information.

71

1 Comment

Interesting four-part series about cell therapy from Fierce Biotech. Definitely worth a full read. Provided the link and a summary for each part of the series below. 𝐏𝐚𝐫𝐭 𝟏: 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐟𝐚𝐜𝐞𝐬 𝐚 𝐫𝐞𝐜𝐤𝐨𝐧𝐢𝐧𝐠: '𝐖𝐞'𝐯𝐞 𝐥𝐨𝐬𝐭 𝐨𝐮𝐫 𝐥𝐮𝐬𝐭𝐞𝐫 𝐢𝐧 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬' 𝐀𝐫𝐭𝐢𝐜𝐥𝐞 𝐥𝐢𝐧𝐤: https://lnkd.in/gGp9RCgr 𝐒𝐮𝐦𝐦𝐚𝐫𝐲 𝐨𝐟 𝐏𝐚𝐫𝐭 𝟏 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐢𝐧 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲: -Decline in interest and performance of autologous CAR-T therapies. -Market challenges and manufacturing issues. -Shift in focus towards autoimmune conditions. 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐒𝐡𝐢𝐟𝐭𝐬: -Major pharma companies like Sanofi and Bristol Myers Squibb (BMS) are restructuring and streamlining cell therapy efforts. -BMS closed a research center and signed deals focusing on autoimmune therapies. -Sanofi discontinued Kiadis, a business focused on natural killer cell therapies. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞: -Mixed results for approved cell therapies, with Gilead’s Yescarta as a notable success. -Bispecifics are outperforming cell therapies in cancer care. 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐚𝐧𝐝 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬: -Slow progress in solid tumors and high relapse rates. -Emerging allogeneic (donor cell) therapies show promise but face setbacks. 𝐅𝐮𝐭𝐮𝐫𝐞 𝐃𝐢𝐫𝐞𝐜𝐭𝐢𝐨𝐧𝐬: -Companies like Allogene and Caribou Biosciences are exploring new gene-editing tools and next-gen therapies. -Focus on developing in vivo CAR and allogeneic products. -Continued commitment to advancing cell therapy despite current challenges. 𝐊𝐞𝐲 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: -Industry needs to justify ongoing investment in cell therapy. -Potential for market acceptance of new technologies. -Ongoing development in gene-edited and allogeneic therapies may bring breakthroughs. Part 2: https://lnkd.in/gcpuXmMV

10

"In this manuscript, we demonstrate for the first time that a PolySialic Acid-Coated Nanoparticle (PolySia-NP) formulation regulates disease-associated inflammatory complement activity,” says Sheri Peterson, PhD, Sr. Scientist, Neurosciences, at Aviceda Therapeutics. “Alongside our recent work showing PolySia-NP–mediated resolution of disease-associated pro-inflammatory macrophages, these new findings support our ongoing clinical trials of PolySia-NPs for GA/AMD and our pre-clinical programs." You can read the piece that Dr. Peterson and colleagues published in the journal Pharmaceuticals here: https://lnkd.in/e-GTJsRV

40

Unlocking the power of single-cell data! #NIH researchers develop #PERCEPTION (PERsonalized Single-Cell Expression-Based Planning for Treatments In ONcology), a novel precision oncology pipeline that leverages single-cell tumor data to model and predict personalized treatment responses. This breakthrough paves the way for more effective treatments. Quick Read: https://lnkd.in/gJUPTq8w #bioinformatics #cancer #cancertreatment #personalizedmedicine #AI #health #publichealth #sciencenews #biotechnology

1